🔴 20/20 Biolabs is trading 5% down today after Nasdaq cited sub-$1 price and equity shortfall

20/20 Biolabs is trading $0.50 (-5.18%) after Nasdaq cited a sub-$1 bid price and stockholders’ equity below the required $2.5 million threshold.

• On September 15, 2026, the stock was down 5.18% after closing at $0.52 on September 14.
• Equity was reported at $1.62 million, and a compliance plan is due within 45 days.
• Broader risk-off trading and biotech weakness may also be adding pressure.